Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Clinical trial NCT02925533 · TERMINATED

Trial details

NCT number

NCT02925533

Sponsor

Mark Pomerantz, MD

Status

TERMINATED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2016-12-14

Primary completion

2017-06-01

Enrollment

1

View on ClinicalTrials.gov